Belgium pharma firm opens Canadian operation

Toronto, ON – UCB, a Belgium-based global biopharmaceutical company, has announced the expansion of its North American operations with the opening of an affiliate in Canada, called UCB Pharma Canada.

Research at UCB is focused in the areas of central nervous system disorders, immune and inflammatory disorders, allergy and respiratory diseases, as well as oncology. Based in Burlington, ON, the company says it will be working to secure regulatory approval for its new biotherapeutic agent certolizumab pegol.